GT838

GT838 is a preclinical-stage degrader-antibody conjugate (DAC) being developed by Gluetacs Therapeutics for the treatment of anaplastic large cell lymphoma (ALCL). As a DAC, it represents an innovative therapeutic modality that combines the high targeting specificity of a monoclonal antibody with the catalytic protein-degradation power of a degrader payload, such as a PROTAC or molecular glue. This approach is designed to selectively deliver the degrader to target-expressing cancer cells, thereby potentially overcoming the limitations of traditional antibody-drug conjugates (ADCs) by degrading key oncogenic drivers rather than simply delivering cytotoxic agents. While the specific molecular target of the antibody and the identity of the degrader payload have not been publicly disclosed in the company's pipeline, the drug is specifically positioned for ALCL, a type of non-Hodgkin lymphoma.